. 2016 Oct 13;14:11. doi: 10.1186/s12962-016-0060-5

Table 1.

Annual absolute percentage change in femoral neck BMD: observed data and scenarios for extrapolated

Year	On treatment^a			Off treatment
	Observed^b	Extrapolated^c		Observed^b	Extrapolation scenarios^c
	Observed^b	Base case	Sensitivity scenario	Observed^b	Base case	Sensitivity scenario
1	2.82			0.14
2	1.22			−0.38
3	0.94			−0.69
4	0.98				−0.53	−0.69
5	0.34				−0.53	−0.69
6		0.66	0.87		−0.53	−0.69
7		0.66	0.87		−0.53	−0.69
8		0.66	0.87		−0.53	−0.69
9		0.66	0.87		−0.53	−0.69
10		0.66	0.87		−0.53	−0.69

^aAnnual percentage changes in BMD assumed to be equal for patients remaining on treatment with either denosumab or alendronate

^bRef. [6]

^cBase case extrapolations equal to average effects in last two years, sensitivity analyses based on average effect in last three years on treatment and in last year off treatment